Your browser doesn't support javascript.
loading
CRISPR screens identify gene targets at breast cancer risk loci.
Tuano, Natasha K; Beesley, Jonathan; Manning, Murray; Shi, Wei; Perlaza-Jimenez, Laura; Malaver-Ortega, Luis F; Paynter, Jacob M; Black, Debra; Civitarese, Andrew; McCue, Karen; Hatzipantelis, Aaron; Hillman, Kristine; Kaufmann, Susanne; Sivakumaran, Haran; Polo, Jose M; Reddel, Roger R; Band, Vimla; French, Juliet D; Edwards, Stacey L; Powell, David R; Chenevix-Trench, Georgia; Rosenbluh, Joseph.
Afiliação
  • Tuano NK; Cancer Research Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.
  • Beesley J; Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • Manning M; Cancer Research Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.
  • Shi W; Functional Genomics Platform, Monash University, Clayton, VIC, Australia.
  • Perlaza-Jimenez L; Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • Malaver-Ortega LF; Cancer Research Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.
  • Paynter JM; Bioinformatics Platform, Monash University, Clayton, VIC, Australia.
  • Black D; Functional Genomics Platform, Monash University, Clayton, VIC, Australia.
  • Civitarese A; Cancer Research Program and Department of Biochemistry and Molecular Biology, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.
  • McCue K; Development and Stem Cells Program, Monash Biomedicine Discovery Institute, Clayton, VIC, Australia.
  • Hatzipantelis A; Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • Hillman K; Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • Kaufmann S; Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • Sivakumaran H; Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • Polo JM; Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • Reddel RR; Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • Band V; Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • French JD; Development and Stem Cells Program, Monash Biomedicine Discovery Institute, Clayton, VIC, Australia.
  • Edwards SL; Cancer Research Unit, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW, Australia.
  • Powell DR; Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, NE, USA.
  • Chenevix-Trench G; Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
  • Rosenbluh J; Cancer Program, QIMR Berghofer Medical Research Institute, Brisbane, Australia.
Genome Biol ; 24(1): 59, 2023 03 29.
Article em En | MEDLINE | ID: mdl-36991492
BACKGROUND: Genome-wide association studies (GWAS) have identified > 200 loci associated with breast cancer risk. The majority of candidate causal variants are in non-coding regions and likely modulate cancer risk by regulating gene expression. However, pinpointing the exact target of the association, and identifying the phenotype it mediates, is a major challenge in the interpretation and translation of GWAS. RESULTS: Here, we show that pooled CRISPR screens are highly effective at identifying GWAS target genes and defining the cancer phenotypes they mediate. Following CRISPR mediated gene activation or suppression, we measure proliferation in 2D, 3D, and in immune-deficient mice, as well as the effect on DNA repair. We perform 60 CRISPR screens and identify 20 genes predicted with high confidence to be GWAS targets that promote cancer by driving proliferation or modulating the DNA damage response in breast cells. We validate the regulation of a subset of these genes by breast cancer risk variants. CONCLUSIONS: We demonstrate that phenotypic CRISPR screens can accurately pinpoint the gene target of a risk locus. In addition to defining gene targets of risk loci associated with increased breast cancer risk, we provide a platform for identifying gene targets and phenotypes mediated by risk variants.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Estudo de Associação Genômica Ampla / Neoplasias Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Animals Idioma: En Revista: Genome Biol Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Estudo de Associação Genômica Ampla / Neoplasias Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Animals Idioma: En Revista: Genome Biol Ano de publicação: 2023 Tipo de documento: Article